NICE are happy to share some success of their guidance on non-invasive prenatal testing (NIPT) for fetal rhesus-D (RHD) status.
There are now more than 25 sites running over 1000 tests every month. A further 17 sites are due to offer the test by April 2018 and NHS Blood & Transplant expect full national roll-out by 2021/22. This is great news and shows that organisations across the system are implementing NICE best practice to help provide the best possible care to expectant mums with their newborns.
One such organisation is the Antenatal Clinic at Yeovil District Hospital NHS Foundation Trust. Natalie Phipps, Antenatal and Newborn Screening Co-ordinator, Antenatal Clinic Lead and Bereavement Midwife was integral in implementing the test at Yeovil:
“Implementation of the test has meant that we have prevented unnecessary administration of blood products (anti-D immunoglobulin) and their associated risk and avoided painful injections for women where the NIPT for fetal RHD genotype is negative. We’ve also seen a reduction in the number of antenatal anti-D prophylactic clinic appointments, and the amount of anti-D immunoglobulin. Additionally, the test has reduced the need for medical interventions and therefore has reduced anxiety of having them among expectant mums.”
To find out more on the guidance and its resource tools, visit the NICE webpage